Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Investing.com - Castle Biosciences reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Castle Biosciences announced earnings per share of $-0.77 on revenue of $37.01M. Analysts polled by Investing.com EPS of $-0.88 on revenue of $34.85M.
Castle Biosciences 's are down 58% and is trading at $21.94 , still down 64.87% from its 52 week high of $62.45 set on Monday, November 8, 2021.
Castle Biosciences follows other major Healthcare sector earnings this month
Castle Biosciences's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.9B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar